- Home
- AARD vs AREN Comparison
AARD vs AREN Comparison
Compare AARD & AREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | AREN |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.9M | 233.1M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AARD | AREN |
|---|---|---|
| Price | $13.38 | $4.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $30.63 | $12.00 |
| AVG Volume (30 Days) | 178.7K | ★ 243.3K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.66 |
| Revenue | N/A | ★ $142,815,000.00 |
| Revenue This Year | N/A | $13.89 |
| Revenue Next Year | N/A | $13.81 |
| P/E Ratio | ★ N/A | $6.68 |
| Revenue Growth | N/A | ★ 6.72 |
| 52 Week Low | $4.88 | $1.05 |
| 52 Week High | $19.58 | $10.05 |
Technical Indicators
Market Signals| Indicator | AARD | AREN |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 47.69 |
| Support Level | $9.18 | $3.93 |
| Resistance Level | $10.44 | $4.26 |
| Average True Range (ATR) | 0.91 | 0.33 |
| MACD | 0.46 | 0.08 |
| Stochastic Oscillator | 94.75 | 72.83 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.